European Biopharmaceutical Review |
 |
|
|
|
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| With the IM market now thought to be worth £1 billion a year, The Life Science Love Affair with Interim Management is elucidated by Perry Evans of RSA |
|
|
| It has now been several months since the implementation of a European regulation designed to encourage the development of medicines for children. In Child’s Play, Dr Duncan Curley of McDermott Will & Emery UK LLP reviews measures taken to put the new legislation into action |
|
|
|
| Business strategies that rely on later generation advances must be careful not to fall foul of the law of obviousness. In her in-depth article, Jen Zarutskie at Foley Hoag examines the Patently Obvious |
|
|
| One person’s junk is another person’s treasure: in Biotech Bootsale, Michael O’Sullivan and Richard Brown at Plexus Ventures apply this principle to non-strategic assets, finding that better value is often realised by selling to the highest bidder |
|
|
| As new technologies emerge from universities into the business world, many academics are finding highly lucrative returns. Nicos Nicolaou at the Tanaka Business School, Imperial College London, helps pave the way for A Spinning Streak: A Four-Dimensional Perspective on University Spinouts |
|
|
|
| Expectations are high for a cross-industry boom in microfluidics. Géraldine Andrieux-Gustin at Yole Développement provides a closer look at the implications for life sciences, in Microfluidics: Just a Drop in the Ocean? |
|
|
| In Cells, Gels and Alginates, Are Kristiansen, Jan Egil Melvik and Therese Andersen at NovaMatrix tackle the technological challenges relating to alginate purity, biocompatibility and formulations |
|
|
| Our ageing population is placing demands on specialist bone tissue companies for new therapeutic tools. Ronan Le Bot at Atlantic Bone Screen SAS takes a look at a few Skeletons in the Closet |
|
|
| Antibody Conjugates Promise to Deliver – site specific delivery is one of many applications for which antibodies are proving useful. Shane Olwill, Richard Buick and Christopher Scott at Fusion Antibodies outline the expectations |
|
|
| Kate Rowley at Nexxus tracks the myriad benefits of Systems and Networks, with reference not only to biological systems but also to the wider bioscience business community |
|
|
| Existing therapies for the treatment of rheumatoid arthritis can be expensive; Dr Hans Christian Thørgersen of Borean Pharma finds Rheum for Improvement |
|
|
|
|
| High attrition rates lead to costly failures; in Bound but not Gagged, Biacore’s Gary Franklin investigates how binding kinetics are unlocking more successful compounds |
|
|
| As cheap, accurate biosensors become more widespread, Mark Rodgers and Paul Millner at the University of Leeds consider the fashion for biosensors, in Biosensors: Rapid, Preparation-Free Measurement |
|
|
|
| Michael Rosenberg of Health Decisions discusses a strategy that allows researchers to alter clinical studies based on analysis of incomplete results, in Adaptive Research: New Leverage for Biotech |
|
|
| In Life after Death, Ann-Christin Malmborg Hager and Christina Furebring at Alligator Bioscience AB and Philippe Stas at AlgoNomics look at the growing trend for reinstating abandoned clinical trials |
|
|
| Adjuvants are changing our understanding of carrier system technology for vaccine delivery. In Natural and Synthetic Additives, Vincent W Bramwell and Yvonne Perrie at the University of Aston illuminate recent developments |
|
|
| Tanja Beilke, Oliver Halbig and Andreas Richter at NewLab BioQuality AG avoid the potential dangers of contaminants, in Without a Trace |
|
|
| With TeGenero still very much in the public consciousness, Anthony Warnock-Smith at Morgan Lewis lays down The Legal Implications of Phase I Clinical Trials |
|
|
|
| In Environmental Exposure, Brigitte van Noorloos at NOTOX provides guidance on avoiding biopharma’s potentially harmful environmental impact |
|
|
| Once a patent has been granted, the profit clock starts ticking. Dale McQueen at Lanner Group discusses the predictions made possible by simulation, in Against the Clock |
|
|
| In Pushing Biobank Standardisation, Dr Achim Quandt of QIAGEN GmbH makes the case for closer collaboration between biobanks and better systems for tissue management |
|
|
| Moving on Up: The Cultivation of Upstream Strategies. Cell line production can always be made more efficient, both in terms of speed and cost; Andreas Herrmann at Celonic suggests one useful approach |
|
|
| Botulinum neurotoxins can be lethal even in small doses, and yet they are also an approved therapy for a variety of debilitating conditions. John A Chaddock and Keith Foster at Syntaxin Ltd resolve the paradox of a Novel Therapeutics from a Toxin |
|
|
|
| In Ontario’s Biopharma Boom, Bill Mantel at the Ontario Ministry of Research characterises the region’s thriving biopharmaceutical sector |
|
|
| Géraldine Filippi at the Invest in France Agency, London, evaluates recent outlays from abroad, in French Connection: A Record for Foreign Investment |
|
|
|
|
|
